Introduction {#Sec1}
============

The SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) pandemic has caused many deaths from coronavirus disease 2019 (COVID-19) \[[@CR1]--[@CR8]\]. The outbreak began in December 2019 in Wuhan city, Hubei province, China \[[@CR9]--[@CR16]\]. There are several studies or risk factors for death from COVID-19 but most have relatively few subjects and come from 1 or 2 centers \[[@CR17]--[@CR26]\]. We analyzed prognostic covariates for death in 1859 subjects with confirmed COVID-19 from 7 centers in Wuhan city from January 20 to April 4, 2020. Curiously, we found COVID-19 progressed similarly until day 10 after admission but progressed more slowly in the cohort of subjects who died compared with those recovering, possibly because of therapy interventions \[[@CR27], [@CR28]\]. Subjects who died had a greater frequency of comorbidities before COVID-19 and complications after developing COVID-19. We were able to show a correlation between likelihood of death and several hematological and other laboratory covariates at diagnosis.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

From 20 January to 4 April 2020, all consecutive patients ≥18 years were enrolled from Union Hospital (main part, Union West Hospital and Union Tumor Hospital), Wuhan Central Hospital, General Hospital of Central Theater Command, PLA, Wuhan Third Hospital and Wuhan Jin-Yin-Tan Hospital. These hospitals were reconstructed and designated as COVID-19 treatment centers. Between February 4 and February 18, 2020 persons with clinical symptoms and a lung computed tomography (CT) scan consistent with COVID-19 were diagnosed as having COVID-19 without confirmation of SARS-CoV-2-infection by quantitative reverse transcript polymerase chain reaction (qRT-PCR). After hospitalization subjects were tested by qRT-PCR to confirm the diagnosis and monitor their course. Beginning 4 March, 2020, anti-SARS-CoV-2 IgM and/or IgG antibodies were assayed at Union Hospital and Wuhan Central Hospital by the centers to confirm the diagnosis and to evaluate suspected cases of COVID-19 which were qRT-PCR-negative \[[@CR29]\]. Subjects in whom we could not confirm SARS-CoV-2-infection by a qRT-PCR, IgM/IgG assay, or either were excluded from the study. Subjects recovering from COVID-19 were discharged and transferred to designated hotels, Fangcang shelter hospitals \[[@CR30]\] or Leishenshan Hospital for 2--4 weeks of isolation or further care if needed. The study was approved by the Ethics Committees of Union Hospital (2020-0095) and of Wuhan Central Hospital (2020-007). Written and orally informed consent from subjects was waived by the Ethics Committees.

Data collection {#Sec4}
---------------

We obtained epidemiological, demographic, clinical, laboratory, radiological, therapy, and outcomes data from electronic medical records using a standardized data collection form. Therapies included antibiotics, anti-viral therapy, corticosteroids, and supportive care including supplemental oxygen, mechanical ventilation (with and without intubation), and extracorporeal membrane oxygenation (ECMO). Data were independently entered and cross validated by two physicians (WH and JY). A third researcher (QL) adjudicated discordances. Missing data were retrieved from the relevant hospital.

SARS-CoV-2 testing and laboratory covariants {#Sec5}
--------------------------------------------

Methods for diagnosis of SARS-CoV-2-infection by qRT-PCR are described \[[@CR24]\]. Before January 11, 2020 testing was done by a few institutions such as the Chinese Center for Disease Control and Prevention. Beginning January 11, 2020, qRT-PCR testing was done at local Centres for Disease Control and Prevention and from January 27, 2020 in the study hospitals. Beginning March 4, 2020 IgM/IgG antibodies to SARS-CoV-2 were tested at Union Hospital and after March 5, 2020 in Wuhan Central Hospital. Nasopharyngeal swab specimens were obtained every other day if there was clinical improvement judged by clinical signs and symptoms and lung CT scan. Subjects recovering were discharged after ≥2 negative qRT-PCR tests \>24 h apart. Studies on admission included a CBC and differential, biochemistry panel, coagulation profile, and tests of inflammation including C-reactive protein (CRP), procalcitonin, lactate dehydrogenase (LDH), and ferritin. All subjects had a lung CT scan.

Definitions {#Sec6}
-----------

Exposure history was defined as exposure to persons with confirmed SARS-CoV-2-infection or visiting the Huanan Wholesale Seafood Market, possible origin site of the SARS-CoV-2 epidemic in Wuhan city. Smoking history was defined as current or former smoker (stopping \>5 years ago) with exposure of ≥20 cigarettes per day for ≥1 year (1 pack year). Fever was defined as temperature ≥37.3 °C. Diagnosis of bacterial infection required ≥1 positive culture or a positive antigen detection test. Acute kidney injury, acute respiratory distress syndrome (ARDS), and acute cardiac injury were diagnosed according to guidelines or as reported \[[@CR24], [@CR31], [@CR32]\]. Liver damage was defined as more than 2x upper limit of normal. Severity of COVID-19 was classified as; (1) mild; (2) moderate; (3) severe; or (4) critical according to the Chinese management guideline for COVID-19 (version 7) \[[@CR29], [@CR33]\]. Recovery was defined as complete resolution of clinical signs and symptoms, normalization of the lung CT scan (if abnormal) and ≥2 negative qRT-PCR tests for SARS-CoV-2. Subjects dying of unrelated causes were excluded from analyses of COVID-19-related deaths. Invasive and noninvasive mechanical ventilations were defined as mechanical ventilation with and without intubation.

Statistical analysis {#Sec7}
--------------------

Demographics and clinical covariates were presented using descriptive statistics with frequencies (percentage) for discrete variables and median (IQR) and range for continuous variables. Medians were compared using independent group *t* test and Mann--Whitney test for normally and abnormally distributed data. Proportions for categorical variables were compared by *χ*^2^ test. Missing data were ignored without multiple imputations. Covariates considered for correlations with death included age, sex, occupation, signs and symptoms, laboratory and radiological findings, smoking history, comorbidities including arterio-sclerotic cardio-vascular disease (ASCVD), arterial hypertension, diabetes mellitus, chronic obstructive pulmonary disease (COPD), cancer, ARDS, infection, septic shock, acute renal failure, myocardial infarction, liver injury, gastro-intestinal bleeding, disseminated vascular coagulation, and multiple organ failure. Neutrophil-to-lymphocyte ratio (NLR), D-dimer and serum creatine (Scr) were log~10~ transformed before the analyses because of non-normal distributions. Uni- and multi-variable Cox regression models were used to evaluate associations of covariants with risk of death. R version 3.5.2 was used for statistical analyses. For unadjusted comparisons, a two-sided alpha of \<0.05 was considered significant. Analyses were not adjusted for multiple comparisons.

Results {#Sec8}
=======

Admission clinical covariates {#Sec9}
-----------------------------

From January 20 to April 4, 2020, 3559 subjects who died or had been discharged with clinical- or qRT-PCR-confirmed COVID-19 \[[@CR34], [@CR35]\] were enrolled. As shown in Fig. [1](#Fig1){ref-type="fig"}, 1859 subjects were included for analysis, with SARS-CoV-2-infection confirmed in 1790 subjects by qRT-PCR and by antibody testing in 69. Of the 1859 subjects, 208 died (11%), 157 (8%) recovered and discharged but remained hospitalized in other units for 2--4 weeks of recovery-related care, and 1494 (80%) discharged and transferred to COVID-19 designated hotels or Fangcang shelter hospitals \[[@CR30]\] for 2--4 weeks of isolation.Fig. 1Study flow diagram.

Median age was 59 years (Interquartile Range \[IQR\] 45--68 years; Table [1](#Tab1){ref-type="table"}). 806 (43%) were 60--79 years and 122 (7%) \>80 years. 934 subjects were male (50%). 111 (6%) were current or former smokers, 71 (5%), health care provider, and 14 (1%), with pregnancy or puerperium. In total, 4 subjects were exposed at Huanan Seafood Wholesale Market and 78 (4%) had close contact with persons with confirmed SARS-CoV-2 infection. 579 (31%) had hypertension, 268 (14%), ASCVD, 262 (14%), diabetes, 98 (5%), gastro-intestinal disease, 69 (4%), cancer and 61 (3%), COPD. Most common signs and symptoms included fever (*n* = 1448, 78%), shortness of breath (*n* = 716, 39%), dry (*n* = 619, 43%) or wet cough (*n* = 715, 39%), fatigue (*n* = 695, 37%), chills (*n* = 281, 19%) and myalgia (*n* = 315, 17%). Bilateral pneumonia (*n* = 1570, 88%) and Ground-glass opacity (*n* = 1331, 75%) were two most findings in lung CT scan. 34 (2%) subjects had mild, 1170 (63%), moderate, 453 (24%), severe and 202 (11%) critical COVID-19.Table 1Demographic and clinical covariates.Total *n* = 1859Alive *n* = 1651 (89)Died *n* = 208 (11)*P* valueAge, median (IQR), years59 (45, 68)57 (43, 66)70 (63, 78)\<0.001Age distribution\<0.001  \<40 years342 (18)337 (20)5 (2)  40--59 years589 (32)556 (34)33 (16)  60--79 years806 (43)681 (41)125 (60)  ≥80 years122 (7)77 (5)45 (22) Female sex925 (50)870 (53)55 (26)\<0.001 Smoking history111 (6)86 (5)25 (13)\<0.001  Former smoker66 (4)54 (3)12 (6)  Current smoker45 (2)32 (2)13 (7) Health care provider71 (5)69 (6)2 (1)0.008 Pregnancy/Puerperium14 (1)14 (1)0 (0)0.394 Exposure history0.005 Huanan Seafood Market4 (0.2)1 (0.1)3 (1) Close contact with patients78 (4)72 (4)6 (3) Comorbidity  ASCVD268 (14)205 (12)63 (30)\<0.001  Hypertension579 (31)475 (29)104 (50)\<0.001  Diabetes262 (14)203 (12)59 (28)\<0.001  COPD61 (3)49 (3)12 (6)0.039  Cancer69 (4)52 (3)17 (8)\<0.001  Chronic kidney disease45 (2)25 (2)20 (10)\<0.001  Gastro-intestinal disease98 (5)82 (5)16 (8)0.097  Auto-immune disease10 (1)9 (1)1 (1)0.999  Psychiatric disorders7 (0.5)6 (0.5)1 (1)0.586Signs and symptoms  Fever^a^1448 (78)1274 (77)174 (84)0.025  Temperature (°C)^b^36.6 (36.4, 37.0)36.6 (36.4, 37.0)36.8 (36.5, 37.5)\<0.001  Shortness of breath716 (39)572 (35)144 (70)\<0.001  Dry cough619 (43)554 (43)65 (38)0.205  Wet cough715 (39)609 (37)106 (51)\<0.001  Fatigue695 (37)595 (36)100 (48)\<0.001  Nausea or vomiting124 (9)114 (9)10 (6)0.186  Diarrhea243 (13)213 (13)30 (14)0.522  Chills281 (19)236 (18)45 (26)0.015  Rhinorrhea33 (2)30 (2)3 (1)0.999  Myalgia315(17)282 (17)33 (16)0.681  Headache107 (6)101 (6)6 (3)0.061Radiological features  Bilateral pneumonia1570 (88)1402 (87)168 (96)\<0.001  Consolidation326 (18)266 (17)60 (35)\<0.001  Ground-glass opacity1331 (75)1213 (76)118 (69)0.042  Patchy shadows736 (41)664 (41)72 (42)0.81COVID-19 stage\<0.001  Mild34 (2)34 (2)0 (0)  Moderate1170 (63)1162 (70)8 (4)  Severe453 (24)427 (26)26 (13)  Critical202 (11)28 (2)174 (84)Data are median (IQR) or *n* (%).*ASCVD* atherosclerotic cardio- and cerebro-vascular disease, *COPD* chronic obstructive pulmonary disease.^a^≥1 temperature ≥37.3 °C from onset of symptoms to admission.^b^Admission temperature.

Comparison of survivors and nonsurvivors by clinical covariates {#Sec10}
---------------------------------------------------------------

Subjects who died were older (medians 70 versus 57 years; *P* \< 0.001, Table [1](#Tab1){ref-type="table"}), more likely male (74% *versus* 47%; *P* \< 0.001), more likely smokers (13% versus 5%; *P* \< 0.001) and less likely health care providers (1% versus 6%, *P* = 0.008). More subjects who died were exposure at the Huanan Seafood Wholesale Market (1% *versus* 0.1%, *P* = 0.005). Nonsurvivors more likely to have comorbidities of hypertension (50% versus 29%; *P* \< 0.001), ASCVD (30% versus 12%; *P* \< 0.001), diabetes (28% versus 12%; *P* \< 0.001), COPD (6% versus 3%; *P* = 0.039), cancer (8% versus 3%; *P* \< 0.001) and kidney failure (10% versus 2%; *P* \< 0.001). Fever from illness onset to admission (84% versus 77%; *P* = 0.025), shortness of breath (70% versus 35%; *P* \< 0.001), wet cough (51% versus 37%; *P* \< 0.001), fatigue (48% versus 36%; *P* \< 0.001), chills (26% versus 18%; *P* = 0.015), bilateral pneumonia (96% versus 87%; *P* \< 0.001) and lung consolidation on CT scan (35% versus 17%; *P* \< 0.001) were more common in subjects who died. Paradoxically, survivors were more likely to have ground-glass lung opacity on lung CT scan (76% versus 69%; *P* = 0.042). Subjects who died were more likely to have critical COVID-19 on admission (84% versus 2%; *P* \< 0.001) and less likely to have moderate severity (4% versus 70%; *P* \< 0.001).

Comparison of survivors and nonsurvivors by laboratory covariates {#Sec11}
-----------------------------------------------------------------

There were significant differences in admission laboratory covariates between survivors and nonsurvivors (Table [2](#Tab2){ref-type="table"}). Subjects who died had higher median neutrophils (7 × 10 E + 9/L \[IQR 4--10 × 10 E + 9/L\] versus 3  × 10 E + 9/L \[IQR 2--4 × 10 E + 9/L\]; *P* \< 0.001), lower median lymphocytes (0.6 × 10 E + 9/L \[IQR 0.4--0.9 × 10 E + 9/L\] *versus* median 1.2 × 10 E + 9/L \[IQR 0.9--1.6 × 10 E + 9/L\]; *P* \< 0.001), lower median platelets (163 × 10 E + 9/L \[IQR 113--223 × 10 E + 9/L\] versus 207 10 E + 9/L \[IQR 161--268 × 10 E + 9/L\]; *P* \< 0.001) and higher median neutrophil-to-lymphocyte ratios (NLR; 11 \[IQR 6--20\] versus 3 \[IQR 2--4\]; *P* \< 0.001). Nonsurvivors had lower median proportions of CD3-positive cells (60% \[IQR 52--70%\] *versus* 72% \[IQR 63--79%\]; *P* \< 0.001), median proportions of CD8-positive cells (16% \[IQR 11--20%\] versus 24% \[IQR 18--30%\]; *P* \< 0.001), median proportions of NK-cells (8% \[IQR 3--12%\] versus 10%, \[IQR 6--17%\]; *P* = 0.011), and higher proportions of B-lymphocyte (15% \[IQR 9--28%\] versus 12% \[IQR 9--17%\]; *P* = 0.033) and higher median CD4/CD8 ratios (3 \[IQR 2--4\] versus 2 \[IQR 1--3\]; *P* \< 0.001) compared with survivors.Table 2Laboratory covariates on admission.Covariates (normal range)*N*TotalAliveDied*P* valueCBC Neutrophils ×10E + 9/L (1.8--6.3)18163 (2, 5)3 (2, 4)7 (4, 10)\<0.001 Lymphocytes ×10 E + 9/L (1.1--3.2)18471.0 (0.8, 1.6)1.2 (0.9, 1.6)0.6 (0.4, 0.9)\<0.001 Monocytes ×10 E + 9/L (0.1--0.6)18050.4 (0.3, 0.5)0.4 (0.3, 0.5)0.3 (0.2, 0.5)\<0.001 Hemoglobin, g/L (115--150)1433128 (117, 139)128 (117, 139)129 (117, 140)0.539 Platelets ×10 E + 9/L (125--350)1814203 (155, 264)207 (161, 268)163 (113, 223)\<0.001 NLR18143 (2, 5)3 (2, 4)11 (6, 20)\<0.001Inflammation covariates hCRP, mg/L (\<4)9954 (1, 10)3 (1, 10)10 (10, 80)\<0.001 Procalcitonin, ng/ml (\< 0.5)16430.06 (0.05, 0.1)0.05 (0.04, 0.1)0.3 (0.1, 0.6)\<0.001 LDH, U/L (109--245)1729212 (170, 292)201 (165, 261)412 (306, 561)\<0.001 Ferritin, ng/ml (4.6--204)308567 (246, 1218)470 (197, 940)1579 (1206, 2000)\<0.001Coagulation covariates aPTT, s (28--43.5)135634 (30, 38)34 (30, 38)37 (31, 42)\<0.001 Fibrinogen, g/L (2--4)13233.7 (2.9, 4.6)3.7 (2.9, 4.6)4.3 (3.2, 5.1)\<0.001 D-dimer, mg/L (\<0.5)16020.4 (0.2, 1.1)0.4 (0.2, 0.8)2.5 (0.7, 8)\<0.001Biochemical covariates ALT, U/L (5--35)183238 (22, 67)36 (21, 63)58 (30, 139)\<0.001 AST, U/L (8--40)183032 (22, 49)30 (22, 44)64 (40, 140)\<0.001 Total bilirubin, μmol/L (5.1--19)158614 (10, 19)13 (10, 18)24 (15, 36)\<0.001 Creatine kinase, U/L (26--140)149388 (54, 165)81 (52, 135)262 (135, 636)\<0.001 BNP, pg/ml (\< 100)83861 (18, 242)47 (15, 140)467 (121, 1467)\<0.001 Myoglobin, ng/ml (\<140)97235 (21, 73)30 (21, 51)576 (175, 1013)\<0.001 Troponin I, ng/L (\<26.2)10834 (1, 14)3 (1, 8)161 (46, 712)\<0.001 BUN, mmol/L (2.9--8.2)18155 (4, 7)5 (4, 6)15 (9, 27)\<0.001 Scr, μmol/L (44--106)181371 (59, 85)69 (58, 81)108 (76, 256)\<0.001Lymphocyte subsets CD3+, (58--84%)75971 (62, 78)72 (63, 79)60 (52, 70)\<0.001 CD4+, (25--51%)75941 (32, 48)41 (33, 48)37 (28, 46)0.094 CD8+, (14--39%)75923 (17, 30)24 (18, 30)16 (11, 20)\<0.001 NK cell, (3--30%)56110 (6, 16)10 (6, 17)8 (3, 12)0.011 B lymphocyte, (4--18%)56113 (9, 18)12 (9, 17)15 (9, 28)0.033 CD4 + /CD8 + Ratio (0.41--2.72)7552 (1, 3)2 (1, 3)3 (2, 4)\<0.001Cytokines IL-4, pg/ml (0.1--3.2)5053 (2, 4)3 (2, 4)2 (2, 3)0.21 IL-6, pg/ml (0.1--2.9)85710 (4, 42)9 (4, 32)79 (23, 525)\<0.001 IL-10, pg/ml (0.1--5)5054 (3, 6)4 (3, 5)10 (5, 22)\<0.001 TNF-α, pg/ml (0.1--23)5053.3 (2.2, 5.4)3.5 (2.3, 5.6)2.7 (1.9, 3.6)0.009 IFN-γ, pg/ml (0.1--18)5053.1 (2.0, 4.1)3.1 (2.0, 4.1)2.7 (1.8, 4.2)0.313Data are median (IQR).*NLR* neutrophil-to-lymphocyte ratio, *hCRP* high-sensitivity c-reactive protein, *LDH* lactate dehydrogenase, *aPTT* activated partial thromboplastin time, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *BNP* B-type natriuretic peptide, *BUN* blood urea nitrogen, *Scr* serum creatinine, *IL* interleukin, *TNF* tumor necrosis factor, *IFN* interferon.

Subjects who died had longer median aPTT (37 s \[IQR 31--42 s\] versus 34 s \[IQR 30--38 s\]; *P* \< 0.001) and higher median concentrations of fibrinogen (4.3 g/L \[IQR 3.2--5.1 g/L\] versus 3.7 g/L \[IQR 2.9--4.6 g/L\]; *P* \< 0.001) and median D-dimer concentrations (2.5 mg/L \[IQR 0.7--8 mg/L\] versus 0.4 mg/L \[IQR 0.2--0.8 mg/L\]; *P* \< 0.001).

Subjects who died also had higher median hCRP concentrations (10 mg/L \[IQR 10--80 mg/L\] versus 3 mg/L \[IQR 1--10 mg/L\]; *P* \< 0.001), median procalcitonin concentrations (0.3 ng/ml \[IQR 0.1--0.6 ng/mL\] versus 0.05 ng/ml \[IQR 0.04--0.1 ng/mL\]; *P* \< 0.001), median LDH activities (412 U/L \[IQR 306--561 U/L\] versus 201 U/L \[IQR 165--261 U/L\]; *P* \< 0.001), median ferritin concentrations (1579 ng/mL \[IQR 1206-2000 ng/mL\] versus 470 ng/mL \[IQR 197--940 ng/mL\]; *P* \< 0.001), median IL-6 concentrations (79 pg/mL \[IQR 23--525 pg/mL\] versus 9 pg/mL \[IQR 4--32 pg/mL\]; *P* \< 0.001), median IL-10 concentrations (10 pg/mL \[IQR 5--22 pg/mL\] versus 4 pg/mL\[IQR 3--5 pg/mL\]; *P* \< 0.001) and lower median TNF-α concentrations (2.7 pg/mL \[IQR 1.9--3.6 pg/mL\] versus 3.5 pg/mL \[IQR 2.3--5.6 pg/mL\]; *P* = 0.009).

Subjects who died also had higher median activities of alanine aminotransferase (ALT; 58 U/L \[IQR 30--139 U/L\] versus 36 U/L \[IQR 21--63 U/L\]; *P* \< 0.001), aspartate aminotransferase (AST; 64 U/L \[IQR 40--140 U/L\] versus 30 U/L \[IQR 22--44 U/L\]; *P* \< 0.001), creatine kinase (262 U/L \[IQR 135--636 U/L\] versus 81 U/L \[IQR 52--135 U/L\]; *P* \< 0.001) and median concentrations of total bilirubin (24 μmol/L \[IQR 15--36 μmol/L\] versus 13 μmol/L \[IQR 10--18 μmol/L\]; *P* \< 0.001), b-type natriuretic peptide (BNP; 467 pg/ml \[IQR 121--1467 pg/ml\] versus 47 pg/ml, \[IQR 15--140 pg/ml\]; *P* \< 0.001), myoglobin (576 ng/ml \[IQR 175--1013 ng/ml\] versus 30 ng/ml \[IQR 21--51 ng/ml\]; *P* \< 0.001) and troponin I (161 ng/L \[IQR 46--712 ng/L\] versus 3 ng/L \[IQR 1--8 ng/L\]; *P* \< 0.001), blood urea nitrogen (BUN; 15 mmol/L \[IQR 9--27 mmol/L\] versus 5 mmol/L \[IQR 4--6 mmol/L\]; *P* \< 0.001) and Scr (108 μmol/L \[IQR 76--256 μmol/L\] versus 69 μmol/L \[IQR 58--81 μmol/L\]; *P* \< 0.001).

Complications and treatments for survivors and non-survivors {#Sec12}
------------------------------------------------------------

Subjects who died were more likely to have complications (207 \[99.5%\] versus 1039 \[63%\]; *P* \< 0.001) including ARDS (174 \[84%\] versus 53 \[3%\]; *P* \< 0.001), bacterial infection (180 \[87%\] versus 383 \[23%\]; *P* \< 0.001) and liver damage (102 \[50%\] versus 354 \[22%\]; *P* \< 0.001; Table [3](#Tab3){ref-type="table"}). Nonsurvivors also had higher incidence of heart injury (130 \[63%\] versus 99 \[6%\]; *P* \< 0.001), multiple organ failure (126 \[61%\] versus 3 \[0.2%\]; *P* \< 0.001), acute kidney injury (82 \[39%\] versus 17 \[1%\]; *P* \< 0.001), septic shock (63 \[37%\] versus 1 \[0.1%\]; *P* \< 0.001), abnormal coagulation parameters (47 \[23%\] versus 2 \[0.1%\]; *P* \< 0.001) and gastro-intestinal bleeding (29 \[14%\] versus 5 \[0.3%\]; *P* \< 0.001).Table 3Complications and therapy.Total *n* = 1859Alive *n* = 1651 (89)Died *n* = 208 (11)*P* valueComplications ARDS227 (12)53 (3)174 (84)\<0.001 Bacterial infections563 (30)383 (23)180 (87)\<0.001 Septic shock64 (4)1 (0.1)63 (37)\<0.001 Acute kidney injury99 (5)17 (1)82 (39)\<0.001 Cardiac injury229 (12)99 (6)130 (63)\<0.001 Abnormal LFT456 (25)354 (22)102 (50)\<0.001 Gastro-intestinal bleeding34 (2)5 (0.3)29 (14)\<0.001 Coagulopathy49 (3)2 (0.1)47 (23)\<0.001 Multiple organ failure129 (7)3 (0.2)126 (61)\<0.001Therapy Antibiotics1559 (85)1356 (84)203 (98)\<0.001 Antifungal drugs71 (4)32 (2)39 (20)\<0.001 Oseltamivir757 (41)688 (42)69 (33)0.021 Umifenovir1386 (75)1226 (74)160 (77)0.351 Lopinavir/Ritonavir339 (23)280 (22)59 (35)\<0.001 Interferon387 (21)344 (21)43 (21)0.957 Corticosteroids753 (41)588 (36)165 (80)\<0.001 IVIG506 (29)401 (26)105 (52)\<0.001 High-flow nasal cannula oxygen therapy233 (16)81 (6)152 (89)\<0.001 Noninvasive mechanical ventilation145 (8)27 (2)118 (57)\<0.001 Invasive mechanical ventilation85 (5)12 (1)73 (35)\<0.001 ECMO4 (0.2)1 (0.1)3 (1)0.005 CRRT23 (2)4 (0.3)19 (11)\<0.001Outcomes ICU admission106 (6)36 (2)70 (34)\<0.001 Time from illness onset to ICU admission, median (IQR), days14 (10, 20)14 (10, 21)14 (10, 20)0.962 ICU length of stay, median (IQR), days10 (4, 17)10 (5, 18)10 (4, 16)0.676 Time from illness onset to repeated negative SARS-CoV-2 tests, median (IQR), days22 (17, 28)22 (17, 28)21 (15, 27)0.284 Time from illness onset to admission, median (IQR), days10 (7, 15)10 (7, 16)9 (6, 12)\<0.001 Time from illness onset to progression, median (IQR), days10 (7, 15)10 (6, 14)12 (9, 18)\<0.001 Time from illness onset to outcome, median (IQR), days30 (23, 37)31 (24, 38)21 (14, 28)\<0.001 Time from diagnosis to outcome, median (IQR), days19 (13, 27)20 (14, 28)11 (5, 17)\<0.001 Time from admission to outcome, median (IQR), days18 (12, 23)18 (14, 23)10 (6, 19)\<0.001*LFT* liver function test, *ARDS* acute respiratory distress syndrome, *IVIG* intravenous immunoglobin, *ECMO* extra-corporeal membrane oxygenation, *CRRT* continuous renal replacement therapy, *ICU* intensive care unit.

Also, subjects who died were more likely to receive antibiotics (203 \[98%\] versus 1356 \[84%\]; *P* \< 0.001), antifungal drugs (39 \[20%\] versus 32 \[2%\]; *P* \< 0.001), lopinavir and ritonavir (59 \[35%\] versus 280 \[22%\]; *P* \< 0.001), corticosteroids (165 \[80%\] versus 588 \[36%\]; *P* \< 0.001), intravenous immunoglobin (IVIG; 105 \[52%\] versus 401 \[26%\]; *P* \< 0.001), high-flow nasal cannula oxygen therapy (152 \[89%\] versus 81 \[6%\]; *P* \< 0.001), noninvasive mechanical ventilation (118 \[57%\] versus 27 \[2%\]; *P* \< 0.001), invasive mechanical ventilation (73 \[35%\] versus 12 \[1%\]; *P* \< 0.001), ECMO (3 \[1%\] versus 1 \[0.1%\]; *P* = 0.005) and continuous renal replacement therapy (CRRT) (19 \[11%\] versus 4 \[0.3%\]; *P* \< 0.001).

Nonsurvivors had briefer median intervals from onset of symptoms to admission (9 d \[IQR 6--12 d\] versus 10 d \[IQR 7--16 d\]; *P* \< 0.001) and median intervals from onset of symptoms to death or discharge (21 d \[IQR 14--28\] versus 31 d \[IQR 24--38 d\]; *P* \< 0.001), and from admission to death or discharge (10 d \[IQR\] 6--19 d versus 18 d \[IQR 14--23 d\]; *P* \< 0.001) but longer median intervals from onset of symptoms to progression (median 12 d \[IQR 9--18 d\] versus 10 d \[QR 6--14 d\]; *P* \< 0.001). There were no differences between survivors and nonsurvivors in median intervals from symptoms onset to ICU admission (14 d \[IQR 10--20 d\] versus 14 d \[IQR 10--21 d\]; *P* = 0.962) or median intervals to negative SARS-CoV-2 testing (21 d \[IQR 15--27 d\] versus 22 d \[IQR 17--28 d\]; *P* = 0.284). In total, 178 of the 208 subjects who died (86%) had a positive qRT-PCR test until death.

Risk factors for death {#Sec13}
----------------------

In total, 33 covariants had significant associations with risk of death in uni-variable analyses, 8 of which remained significant in multi-variable analyses including age (HR = 1.04 \[1.03, 1.06\]; *P* \< 0.001), smoking history (HR = 1.84 \[1.17, 2.92\]; *P* = 0.009), temperature value (°C) at admission (HR = 1.32 \[1.07--1.64\]; *P* = 0.009), log~10~ NLR (HR = 3.30 \[2.10, 5.19\]; *P* \< 0.001), admission platelet concentration (HR = 0.996; \[0.994--0.998\]; *P* = 0.001), aPTT on admission (HR = 1.04 \[1.02, 1.05\]; *P* \< 0.001), Log~10~ D-dimer (HR = 3.00 \[2.17, 4.16\]; *P* \< 0.001), and Log~10~ Cr (HR = 4.55 \[2.72, 7.62\]; *P* \< 0.001; Table [4](#Tab4){ref-type="table"}).Table 4Risk factors for death.Uni-variable HR (95% CI)*P* valueMultivariable HR (95% CI)*P* valueClinical covariates Age, years1.07 (1.06--1.08)\<0.0011.04 (1.03--1.06)\<0.001 Female sex (vs male)0.35 (0.26--0.48)\<0.001\.... Smoking history (vs nonsmoking)2.43 (1.59--3.73)\<0.0011.84 (1.17--2.92)0.009 Health care provider (vs non health care provider)0.24 (0.06--0.96)0.044\....Comorbidity (Yes/No) ASCVD2.56 (1.90--3.45)\<0.001\.... Diabetes2.47 (1.82--3.34)\<0.001\.... Hypertension2.21 (1.68--2.90)\<0.001\.... Cancer2.59 (1.58--4.26)\<0.001\....Symptoms and complications (Y/N) Dyspnea6.26 (4.76--8.24)\<0.001\.... Wet cough1.63 (1.24--2.14)0.001\.... ARDS54.21 (37.13--79.14)\<0.001\.... Bacterial infections18.36 (12.16--27.72)\<0.001\.... Temperature at admission (°C)1.50 (1.28--1.75)\<0.0011.32 (1.07--1.64)0.009Laboratory covariates Neutrophils ×10E + 9/L1.23 (1.20--1.26)\<0.001\.... Lymphocytes x10E + 9/L0.07 (0.05--0.10)\<0.001\.... Log~10~ NLR1.06 (1.06--1.07)\<0.0013.30 (2.10--5.19)\<0.001 Platelets x10E + 9/L0.99 (0.99--1.00)\<0.0010.996 (0.994--0.998)0.001 hCRP, mg/L1.02 (1.02--1.02)\<0.001\.... Procalcitonin, ng/ml1.23 (1.18--1.28)\<0.001\.... LDH, U/L1.00 (1.00--1.00)\<0.001\.... Ferritin, ng/ml1.00 (1.00--1.00)\<0.001\.... aPTT, s1.06 (1.04--1.08)\<0.0011.04 (1.02--1.05)\<0.001 Log~10~ D-dimer, mg/L1.09 (1.08--1.11)\<0.0013.00 (2.17--4.16)\<0.001 Total bilirubin, μmol/L1.03 (1.03--1.04)\<0.001\.... Creatine kinase, U/L1.00 (1.00--1.00)\<0.001\.... Troponin I, ng/L1.00 (1.00--1.00)\<0.001\.... BUN, mmol/L1.06 (1.05--1.07)\<0.001\.... Log~10~ Scr, μmol/L1.00 (1.00--1.00)\<0.0014.55 (2.72--7.62)\<0.001 IL-61.00 (1.00--1.00)\<0.001\.... IL-101.00 (1.00--1.00)0.004\.... CD3-positive, %0.95 (0.93--0.97)\<0.001\.... CD8-positive, %0.91 (0.88--0.94)\<0.001\.... CD4/CD8 ratio1.27 (1.18--1.37)\<0.001\....*CI* confidence interval, *ASCVD* atherosclerotic cardio- and cerebro-vascular disease, *ARDS* acute respiratory distress syndrome, *NLR* neutrophil-to-lymphocyte ratio, *hCRP* high-sensitive c-reactive protein, *LDH* lactate dehydrogenase, *aPTT* activated partial thromboplastin time, *BUN* blood urea nitrogen, *Scr* serum creatinine.

We further showed the linear relationship between these covariants except age, smoking history, and temperature at admission and risk of death (Fig. [2](#Fig2){ref-type="fig"}). Based on the steep curve of Log~10~ NLR we conducted a further piecewise linear regression analysis of NLR and death. The results indicate a Log~10~ NLR value of ≥0.4 to ≤1.0 is significantly associated with risk of death (Table [5](#Tab5){ref-type="table"}).Fig. 2The linear relationship between admission covariants and risk of death.(**a**) log10NLR, (**b**) platelet (x 10 E+9/L), (**c**) log10D-dimer (mg/L), (**d**) aPTT (s) and (**e**) log10Scr (μmol/L).Table 5Piecewise linear regression analysis of the effect of Neutrophil-to-lymphocyte ratio (NLR) on risk of death.Hazard ratio (95% CI)*P* valueLog~10~ NLR3.30 (2.10--5.19)\<0.001Log~10~ NLR \< 0.40.44 (0.02--10.09)0.608Log~10~ NLR ≥ 0.4, ≤ 1.014.06 (3.23--61.21)\<0.001Log~10~ NLR \> 1.00.49 (0.17--1.44)0.195

Discussion {#Sec14}
==========

We identified eight hospital admission covariates which are independent risk factors for death in almost 2000 persons with COVID-19 including older age, smoking history, higher body temperature (°C), and levels of D-dimer, aPTT, Scr, platelet, and NLR on admission. Several are reported by others; however, we were unable to confirm other risk factors reported in smaller datasets \[[@CR15], [@CR18]--[@CR21], [@CR23], [@CR24], [@CR26], [@CR36]\].

We identified Log~10~ NLR as an independent risk factor for death with an HR = 14.1 (3.2, 61.2) with Log~10~ values ≥0.4 to ≤1.0 but not otherwise (Table [5](#Tab5){ref-type="table"}). Although higher neutrophil and lower lymphocyte concentrations and higher NLR were previously reported \[[@CR23], [@CR26], [@CR36]--[@CR38]\], Log~10~NLR has not.

There are important limitations to our study. First, not all covariates were available in all subjects including body mass index and SOFA score (a factor for death identified by logistic regression analysis) \[[@CR24]\]. Also, BNP and TNI were reported in different units and were therefore not included for multi-variable Cox regression analyses. Second, at the data lock 65 (1.8%) subjects remained hospitalized and are excluded from our analyses. Third, some covariates such as bacterial coinfection and BUN could not be accurately analysed and interpreted together with other covariants for interactions. Our conclusions although based on a large dataset require confirmation. Nevertheless, they may be useful in predicting outcomes in persons with COVID-19.
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